New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status - New York, May 3-July 25, 2021
- PMID: 34529645
- PMCID: PMC8445378
- DOI: 10.15585/mmwr.mm7037a7
New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status - New York, May 3-July 25, 2021
Abstract
Data from randomized clinical trials and real-world observational studies show that all three COVID-19 vaccines currently authorized for emergency use by the Food and Drug Administration* are safe and highly effective for preventing COVID-19-related serious illness, hospitalization, and death (1,2). Studies of vaccine effectiveness (VE) for preventing new infections and hospitalizations attributable to SARS-CoV-2, the virus that causes COVID-19), particularly as the B.1.617.2 (Delta) variant has become predominant, are limited in the United States (3). In this study, the New York State Department of Health linked statewide immunization, laboratory testing, and hospitalization databases for New York to estimate rates of new laboratory-confirmed COVID-19 cases and hospitalizations by vaccination status among adults, as well as corresponding VE for full vaccination in the population, across all three authorized vaccine products. During May 3-July 25, 2021, the overall age-adjusted VE against new COVID-19 cases for all adults declined from 91.8% to 75.0%. During the same period, the overall age-adjusted VE against hospitalization was relatively stable, ranging from 89.5% to 95.1%. Currently authorized vaccines have high effectiveness against COVID-19 hospitalization, but effectiveness against new cases appears to have declined in recent months, coinciding with the Delta variant's increase from <2% to >80% in the U.S. region that includes New York and relaxation of masking and physical distancing recommendations. To reduce new COVID-19 cases and hospitalizations, these findings support the implementation of a layered approach centered on vaccination, as well as other prevention strategies such as masking and physical distancing.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
Figures


References
-
- Food and Drug Administration. COVID-19 vaccines. Silver Spring, MD: US Department of Health and Human Services; Food and Drug Administration; 2021. Accessed July 29, 2021. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-dise....
-
- Pilishvili T, Fleming-Dutra KE, Farrar JL, et al.; Vaccine Effectiveness Among Healthcare Personnel Study Team. Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel—33 U.S. sites, January–March 2021. MMWR Morb Mortal Wkly Rep 2021;70:753–8. 10.15585/mmwr.mm7020e2 - DOI - PMC - PubMed
-
- CDC. COVID-19 vaccine breakthrough case investigation and reporting. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. Accessed July 29, 2021. https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-ca...
-
- Israel Ministry of Health. Decline in vaccine effectiveness against infection and symptomatic illness. Jerusalem, Israel: Israel Ministry of Health; 2021. Accessed July 29, 2021. https://www.gov.il/en/departments/news/05072021-03.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous